## Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form 4

<b>CURIVI 4</b> UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       OMB         Number:       OMB	PROVAL 3235-0287 January 31,							
Washington, D.C. 20549 Number:								
	January 31.							
Check this box if no longer subject to Section 16. Form 4 or	2005 verage							
Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940								
(Print or Type Responses)								
MADDON PAUL J Symbol Issuer PROGENICS PHARMACEUTICALS INC IPGNX1	(Check all applicable)							
	title Other (specify							
Filed(Month/Day/Year)       Applicable Line)         _X_ Form filed by One Reporting Per	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person							
TARRYTOWN, NY 10591     Form filed by More than One Rep Person	porting							
(City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficial	y Owned							
Security       (Month/Day/Year)       Execution Date, if       TransactionAcquired (A) or       Securities       Form: Direct       I         (Instr. 3)       any       Code       Disposed of (D)       Beneficially       (D) or Indirect       I         (Month/Day/Year)       (Instr. 8)       (Instr. 3, 4 and 5)       Owned       (I)       0         (A)       or       (A)       or       Reported       Transaction(s)       (Instr. 3 and 4)	7. Nature of indirect Beneficial Ownership Instr. 4)							
Code V Amount (D) Price (Instr. 5 and 4) Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.								

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisab Expiration Date (Month/Day/Year		7. Title and Ar Underlying Se (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title A	
Non-Qualified Stock Option (right to buy)	\$ 4.47	06/17/2014		A	20,000	06/17/2014 <u>(1)</u>	06/17/2024	Common Stock	

## Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form 4

## **Reporting Owners**

Reporting Owner Name / Address		Relationships					
Toporting o when a	Director	10% Owner	Officer	Other			
MADDON PAUL J 777 OLD SAW MILI TARRYTOWN, NY		Х					
Signatures							
/s/ Paul J. Maddon	06/19/2014						
<u>**</u> Signature of Reporting Person	Date						

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) This stock option becomes exercisable immediately, on the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.